Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Edwards Lifesciences Corp. (NYSE:EW)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Edwards Lifesciences Corp. for $13.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Edwards Lifesciences Corp. pages available today for free:

Cash Flow Statement
Quarterly Data

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Edwards Lifesciences Corp., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
3 months ended: Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Net income (loss)
Depreciation and amortization
Non-cash operating lease cost
Stock-based compensation
Inventory write off
Excess tax benefit from stock plans
Impairment charges
Change in fair value of contingent consideration liabilities, net
Deferred income taxes
Purchase of intellectual property
Other
Accounts and other receivables, net
Inventories
Accounts payable and accrued liabilities
Income taxes
Prepaid expenses and other current assets
Litigation settlement accrual
Other
Changes in operating assets and liabilities
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Net cash provided by operating activities
Capital expenditures
Deposit of cash in escrow
Purchases of held-to-maturity investments
Proceeds from held-to-maturity investments
Purchases of available-for-sale investments
Proceeds from available-for-sale investments
Investments in intangible assets
Acquisitions
Payment for acquisition option
Issuances of notes receivable
Other
Net cash (used in) provided by investing activities
Proceeds from issuance of debt, net
Payments on debt and finance lease obligations
Purchases of treasury stock
Equity forward contract related to accelerated share repurchase agreement
Excess tax benefit from stock plans
Proceeds from stock plans
Payment of contingent consideration
Other
Net cash provided by (used in) financing activities
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash
Net increase (decrease) in cash, cash equivalents, and restricted cash

Based on: 10-K (filing date: 2021-02-12), 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Edwards Lifesciences Corp.’s net cash provided by operating activities decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Edwards Lifesciences Corp.’s net cash (used in) provided by investing activities decreased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Edwards Lifesciences Corp.’s net cash provided by (used in) financing activities increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.